Mckinley Carter Wealth Services buys $2,653,348 stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Mckinley Carter Wealth Services scooped up 387 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 12,070 shares of C R Bard Inc which is valued at $2,653,348.C R Bard Inc makes up approximately 1.35% of Mckinley Carter Wealth Services’s portfolio.

Other Hedge Funds, Including , Yacktman Asset Management Lp reduced its stake in BCR by selling 470,594 shares or 36.85% in the most recent quarter. The Hedge Fund company now holds 806,300 shares of BCR which is valued at $177,248,929. C R Bard Inc makes up approx 1.44% of Yacktman Asset Management Lp’s portfolio.Farmers Trust Co reduced its stake in BCR by selling 20 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 17,765 shares of BCR which is valued at $4,085,950. C R Bard Inc makes up approx 1.29% of Farmers Trust Co’s portfolio.British Columbia Investment Management Corp reduced its stake in BCR by selling 10,927 shares or 29.79% in the most recent quarter. The Hedge Fund company now holds 25,750 shares of BCR which is valued at $6,154,250. C R Bard Inc makes up approx 0.05% of British Columbia Investment Management Corp’s portfolio.

C R Bard Inc opened for trading at $220.22 and hit $221.73 on the upside on Thursday, eventually ending the session at $221.42, with a gain of 0.72% or 1.59 points. The heightened volatility saw the trading volume jump to 3,97,077 shares. Company has a market cap of $16,264 M.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *